Vaccines and Melanoma

Hematology/Oncology Clinics of North America

Volumn 28, Issue 3, 2014, Pages 559-569

  Ott, Patrick A ^a,b   Fritsch, Edward F ^a,c   Wu, Catherine J ^a,b   Dranoff, Glenn ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

Immunotherapy; Melanoma; Neoantigen; Vaccine

Indexed keywords

BCG VACCINE; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HILTONOL; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; IPILIMUMAB; MELANOMA ANTIGEN 3; MELANOMA VACCINE; OLIGODEOXYNUCLEOTIDE; ONAMELATUCEL L; PEPTIDE VACCINE; PROGRAMMED DEATH 1 LIGAND 1; TALIMOGENE LAHERPAREPVEC; UNCLASSIFIED DRUG; ANTIGEN; CANCER VACCINE;

CANCER IMMUNOTHERAPY; CANCER PATIENT; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MELANOMA; METASTATIC MELANOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY; BIOLOGICAL MODEL; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG EFFECTS; IMMUNOLOGY; REGULATORY T LYMPHOCYTE; SKIN NEOPLASMS;

ANTIGENS; CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNITY, CELLULAR; MELANOMA; MODELS, IMMUNOLOGICAL; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY;

EID: 84901601896     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2014.02.008     Document Type: Review

References (42)

1. van der Bruggen P., Traversari C., Chomez P., et al. Agene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
2. Cormier J.N., Salgaller M.L., Prevette T., et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997, 3:37-44.
3. Marchand M., van Baren N., Weynants P., et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999, 80:219-230.
4. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998, 4:321-327.
5. Kawakami Y., Eliyahu S., Delgado C.H., et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with invivo tumor rejection. Proc Natl Acad Sci USA 1994, 91:6458-6462.
6. Kawakami Y., Eliyahu S., Delgado C.H., et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994, 91:3515-3519.
7. Chaux P., Vantomme V., Stroobant V., et al. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. JExp Med 1999, 189:767-778.
8. Brichard V., Van Pel A., Wolfel T., et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. JExp Med 1993, 178:489-495.
9. Zeng G., Touloukian C.E., Wang X., et al. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. JImmunol 2000, 165:1153-1159.
10. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-915.
11. Slingluff C.L., Petroni G.R., Yamshchikov G.V., et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. JClin Oncol 2003, 21:4016-4026.
12. Slingluff C.L., Petroni G.R., Olson W.C., et al. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 2009, 15:7036-7044.
13. Kirkwood J.M., Lee S., Moschos S.J., et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res 2009, 15:1443-1451.
14. Schwartzentruber D.J., Lawson D.H., Richards J.M., et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011, 364:2119-2127.
15. Atkins M.B., Lotze M.T., Dutcher J.P., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. JClin Oncol 1999, 17:2105-2116.
16. Sosman J.A., Carrillo C., Urba W.J., et al. Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. JClin Oncol 2008, 26:2292-2298.
17. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. NEngl J Med 2010, 363:711-723.
18. Senzer N.N., Kaufman H.L., Amatruda T., et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. JClin Oncol 2009, 27:5763-5771.
19. Andtbacka R.H., CF, Amatruda T., et al. OPTiM: a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol 2013, 31(Suppl). [Abstract LBA9008].
20. Soiffer R., Lynch T., Mihm M., et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998, 95:13141-13146.
21. Hodi F.S., Schmollinger J.C., Soiffer R.J., et al. ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc Natl Acad Sci USA 2002, 99:6919-6924.
22. Hodi F.S., Butler M., Oble D.A., et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008, 105:3005-3010.
23. Berd D., Sato T., Cohn H., et al. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. Int J Cancer 2001, 94:531-539.
24. Small E.J., Sacks N., Nemunaitis J., et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007, 13:3883-3891.
25. Higano C.S., Corman J.M., Smith D.C., et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008, 113:975-984.
26. Copier J., Dalgleish A. Whole-cell vaccines: a failure or a success waiting to happen?. Curr Opin Mol Ther 2010, 12:14-20.
27. Wood L.D., Parsons D.W., Jones S., et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113.
28. Heemskerk B., Kvistborg P., Schumacher T.N. The cancer antigenome. EMBO J 2013, 32:194-203.
29. Hacohen N., Fritsch E.F., Carter T.A., et al. Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines. Cancer Immunol Res 2013, 1:OF10-OF14.
30. Buckwalter M.R., Srivastava P.K. "It is the antigen(s), stupid" and other lessons from over a decade of vaccitherapy of human cancer. Semin Immunol 2008, 20:296-300.
31. Sensi M., Anichini A. Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy. Clin Cancer Res 2006, 12:5023-5032.
32. Karanikas V., Colau D., Baurain J.F., et al. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001, 61:3718-3724.
33. van Rooij N., van Buuren M.M., Philips D., et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. JClin Oncol 2013, 31:e439-e442.
34. Matsushita H., Vesely M.D., Koboldt D.C., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012, 482:400-404.
35. DuPage M., Mazumdar C., Schmidt L.M., et al. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012, 482:405-409.
36. Bijker M.S., van den Eeden S.J., Franken K.L., et al. CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. JImmunol 2007, 179:5033-5040.
37. Welters M.J., Kenter G.G., Piersma S.J., et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008, 14:178-187.
38. Kenter G.G., Welters M.J., Valentijn A.R., et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008, 14:169-177.
39. Gaucher D., Therrien R., Kettaf N., et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. JExp Med 2008, 205:3119-3131.
40. Jinushi M., Nakazaki Y., Dougan M., et al. MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. JClin Invest 2007, 117:1902-1913.
41. Ali O.A., Huebsch N., Cao L., et al. Infection-mimicking materials to program dendritic cells in situ. Nat Mater 2009, 8:151-158.
42. Ali O.A., Emerich D., Dranoff G., et al. In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci Transl Med 2009, 1:8ra19.